This segment focuses on the development of XCART, a personalized chimeric antigen receptor T cell (CAR T) platform. Research and development activities include engineering T cells to target patient-specific tumor neoantigens, with a focus on B-cell lymphomas. The technology utilizes cell-based therapeutics to target the B-cell receptor on the surface of malignant tumor cells. Patient impact is significant, as CAR T therapy offers a potential treatment for patients with relapsed or refractory B-cell lymphomas. Market positioning is centered on providing a personalized and targeted approach to cancer treatment, with competitive advantages in its focus on neoantigens. Future opportunities include expanding the platform to other cancer types and improving the efficacy and safety of CAR T cell therapies. Regulatory and clinical aspects involve clinical trials to demonstrate safety and efficacy, and seeking regulatory approvals. Partnerships and collaborations are crucial for advancing clinical development and commercialization.

This segment focuses on the development of a DNase I based oncology platform. Research and development activities include expanding research and development collaboration with The Scripps Research Institute to advance DNase platform. The technology utilizes DNase I as an adjunctive treatment to enhance immunotherapeutic efficacy. Patient impact is significant, as DNase I offers a potential treatment to enhance immunotherapeutic efficacy. Market positioning is centered on providing a targeted approach to cancer treatment, with competitive advantages in its focus on DNase I. Future opportunities include expanding the platform to other cancer types and improving the efficacy and safety of DNase I therapies. Regulatory and clinical aspects involve clinical trials to demonstrate safety and efficacy, and seeking regulatory approvals. Partnerships and collaborations are crucial for advancing clinical development and commercialization.